Unlocking Insulin Resistance: Your Path to a Healthier Life!

Dietitian Support for Blood Sugar Spikes.

Q1: What is insulin resistance?

Insulin resistance is a condition where cells in the body especially in the liver, muscles, and adipose tissue fail to respond effectively to insulin. Insulin normally binds to receptors on these cells to trigger glucose uptake for energy. In insulin resistance, this signalling pathway is disrupted due to defects in insulin receptor substrates caused by inflammation and lipid accumulation. The pancreas compensates by producing more insulin, leading to hyperinsulinaemia and impaired glucose metabolism. Over time, this contributes to serious metabolic disorders including type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), and polycystic ovary syndrome (PCOS) .

Q2: How does the insulin signalling pathway get disrupted in insulin resistance?

The insulin receptor’s normal function is impaired by multiple mechanisms including inflammatory molecules and lipid build-up that prevent proper activation of insulin receptor substrates (IRS). Metabolic pathways critical for glucose uptake and glycogen synthesis are inhibited. Additionally, increased phosphorylation at certain sites reduces receptor sensitivity to insulin, further impairing glucose transport into cells .

Q3: What role do mitochondria play in insulin resistance?

Mitochondria, the energy powerhouses of the cell, become dysfunctional in insulin resistance. This dysfunction elevates reactive oxygen species (ROS) production, damaging insulin signalling proteins and energy generation machinery. The reduced energy production impairs glucose uptake, promotes lipid accumulation, and causes lipo-toxicity, all contributing to metabolic dysfunction .

Q4: How do metabolic stress influences insulin resistance?

Excess nutrients and inflammatory triggers cause metabolic stress that prompts the accumulation of unfolded or broken proteins inside cells. This activates inflammatory pathways and lipid imbalances that disrupt insulin signalling and worsen systemic insulin resistance .

Q5: What is the role of inflammation in insulin resistance?

Chronic low-grade inflammation is central to insulin resistance. Key inflammatory mediators include tumour necrosis factor-alpha (TNF-α), which inhibits insulin action and promotes lipid accumulation. Interleukin-6 (IL-6) signals the liver to produce extra glucose and reduces muscle insulin sensitivity under chronic stress. The inflammatory protein C-reactive protein (CRP) serves as a marker of systemic inflammation linked to insulin resistance and cardiovascular disease .

Q6: Do genetic factors influence insulin resistance?

Yes. Some genetic variants impact insulin receptor function and glucose metabolism, increasing risk. Epigenetic modifications such as DNA methylation and histone acetylation can change gene expression based on environmental factors, further contributing to insulin resistance .

Q7: How does body fat contribute to insulin resistance?

Excess fat particularly around internal organs releases substances disrupting insulin function. This fat tissue alters hormone balance and attracts immune cells that cause inflammation, all of which block insulin’s effectiveness and promote insulin resistance .

Q8: How do diet and physical activity affect insulin resistance?

A diet high in refined carbohydrates, saturated fats, and added sugars causes frequent insulin spikes, wearing out pancreatic β-cells, changing gut microbiota, increasing gut permeability, driving systemic inflammation, and reducing fibre intake all leading to impaired glucose metabolism. Lack of exercise reduces the number and quality of glucose transporters in skeletal muscles, diminishes insulin-stimulated glucose uptake, and lowers mitochondrial function, which worsens oxidative stress and metabolic dysregulation .

Q9: What is the impact of gut microbiota changes on insulin resistance?

Alterations in gut bacteria increase lipopolysaccharide (LPS) production that triggers inflammation. Decreased short-chain fatty acid (SCFA) production impairs glucose metabolism, and altered bile acid metabolism affects insulin sensitivity negatively .

Health Risks Associated with Insulin Resistance

Q10: How does insulin resistance contribute to type 2 diabetes and other diseases?

Insulin resistance leads to β-cell dysfunction caused by chronic hyperinsulinaemia and persistent high blood sugar (hyperglycaemia), the hallmark features of type 2 diabetes. It also fosters cardiovascular disease by increasing triglycerides, lowering HDL cholesterol, damaging endothelial function, causing arterial stiffness, and raising blood pressure due to sodium retention. Insulin resistance in the liver causes fat build-up and can progress to liver inflammation (steatohepatitis) and fibrosis. In the brain, insulin resistance sometimes called “Type 3 Diabetes” is linked to amyloid plaque formation and neuroinflammation, which may impair cognition .

Treatment and Management of Insulin Resistance

Q11: What lifestyle changes can improve insulin resistance?

Lifestyle is the first-line treatment. Adopting a balanced diet rich in whole grains, fibre, lean proteins, and healthy fats while cutting processed carbs, added sugars, and saturated fats helps regulate blood sugar and reduce inflammation. Diets like the Mediterranean and low-carb diets have proven benefits. Regular exercise, including both aerobic and resistance training, enhances muscle glucose uptake, improves mitochondrial health, and increases insulin receptor expression. Even modest weight loss (5–10% of body weight) significantly decreases visceral fat, improves lipid metabolism, and restores hormone balance, reducing insulin resistance .

Q12: What medications are used to treat insulin resistance?

Metformin is the most common drug, which reduces liver glucose production, increases peripheral glucose uptake, and improves mitochondrial function. Thiazolidinediones (TZDs) activate PPAR-γ to regulate fat metabolism and decrease inflammation but may cause weight gain. GLP-1 receptor agonists improve insulin secretion, reduce appetite, and support weight loss. SGLT2 inhibitors promote glucose excretion via urine, improving insulin sensitivity and offering cardiovascular benefits .

Q13: Are there emerging therapies for insulin resistance?

New treatments focus on reducing inflammation with agents like salicylates and cytokine inhibitors, improving mitochondrial function with compounds like nicotinamide riboside and coenzyme Q10, and modifying the gut microbiome through probiotics or faecal transplants. Gene and RNA-based therapies are in development targeting disease-causing gene expressions but are still experimental .

Q14: Can natural remedies help improve insulin resistance?

Natural remedies like berberine improve insulin resistance primarily by activating AMP-activated protein kinase (AMPK), a key cellular energy regulator that enhances glucose uptake and reduces inflammation. Myo-inositol supports insulin signalling and helps balance hormones, which is especially beneficial for conditions like PCOS linked to insulin resistance. Other supplements such as cinnamon, chromium, alpha-lipoic acid, and magnesium also show potential by improving insulin sensitivity, reducing oxidative stress, and supporting glucose metabolism, though their effectiveness varies and should be used under professional guidance.

Long-Term Strategies

Q15: What is the best treatment to managing insulin resistance long-term?

A multidisciplinary approach combining lifestyle changes, appropriate medications, and emerging therapies based on individual genetics, metabolism, and lifestyle factors is essential. Personalised care improves outcomes and lowers risks for diabetes, cardiovascular disease, and other complications .

References:

1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846.

2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–194.

3. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307(5708):384–387.

4. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.

5. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13):1546–1558.

6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.

7. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585.

8. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.

9. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.

10. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118.

11. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772.

12. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.

13. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–445.

14. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010;363(24):2339–2350.